Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
24.51
Oct 20 • 3:59 PM ET Dollar change-0.48 Percentage change(-1.92%)
Aftermarket Close
24.46
Aftermarket • 7:54 PM ET Dollar change-0.05 Percentage change(-0.20%)
Oct 20, 1:02 PMFDA manufacturing warning letter sends Baxter shares down 3.8% during Tuesday's regular session
Index
S&P 500
Market Cap
12.67B
Enterprise Value
19.35B
Income
-990.00M
Sales
11.47B
Book/sh
12.00
Cash/sh
4.16
Employees
37500
IPO
May 16, 1961
P/E
-
Forward P/E
11.99
PEG
-
P/S
1.10
P/B
2.04
P/C
5.89
P/FCF
15.55
EV/EBITDA
12.11
EV/Sales
1.69
Quick Ratio
1.32
Current Ratio
1.95
Debt/Eq
1.43
LT Debt/Eq
1.29
Option/Short
Yes / Yes
EPS (ttm)
-1.93
EPS next Y
2.04
EPS next Q
0.52
EPS this Y
-7.21%
EPS next Y
-0.33%
EPS next 5Y
-0.60%
EPS past 3/5Y
24.78% -
Sales past 3/5Y
-8.14% -0.75%
EPS Y/Y TTM
-632.85%
Sales Y/Y TTM
5.36%
EPS Q/Q
11.61%
Sales Q/Q
5.34%
Insider Own
0.64%
Insider Trans
0.00%
Inst Own
109.85%
Inst Trans
4.51%
ROA
-4.74%
ROE
-14.31%
ROIC
-6.96%
Gross Margin
31.85%
Oper. Margin
5.62%
Profit Margin
-8.63%
SMA20
1.23%
SMA50
-1.53%
SMA200
15.83%
Trades
Shs Outstand
517.00M
Shs Float
513.70M
52W High
30.00 -18.30%
52W Low
15.73 55.82%
Volatility
3.38% 2.92%
ATR (14)
0.77
RSI (14)
50.38
Beta
0.67
Rel Volume
1.88
Avg Volume
6.49M
Volume
12,183,841
Perf Week
-1.53%
Perf Month
6.89%
Perf Quarter
12.74%
Perf Half Y
32.56%
Perf YTD
28.26%
Perf Year
5.97%
Perf 3Y
-25.02%
Perf 5Y
-69.83%
Perf 10Y
-49.14%
Prev Close
24.99
Price
24.51
Change %
-1.92%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEPHEN N. OESTERLE REV TRUSTFormer AffiliateMay 18 '26Proposed Sale17.7536,347645,236May 18 04:57 PM
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment sells connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment focuses on the sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
CEOMr. Andrew P. Hider
Executive VP & General CounselMr. David S. Rosenbloom
Group President of Infusion Therapies & PlatformsMs. Maria Soriano
Executive VP & CFOMr. John Terence Rogers
Interim Chief Accounting Officer & ControllerMr. Bernie Heine